Cargando…
Comment on ‘Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)’
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389321/ https://www.ncbi.nlm.nih.gov/pubmed/36917134 http://dx.doi.org/10.1097/JS9.0000000000000292 |
| _version_ | 1785082272711442432 |
|---|---|
| author | Cao, Meili |
| author_facet | Cao, Meili |
| author_sort | Cao, Meili |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10389321 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103893212023-08-01 Comment on ‘Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)’ Cao, Meili Int J Surg Correspondence Lippincott Williams & Wilkins 2023-03-14 /pmc/articles/PMC10389321/ /pubmed/36917134 http://dx.doi.org/10.1097/JS9.0000000000000292 Text en © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
| spellingShingle | Correspondence Cao, Meili Comment on ‘Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)’ |
| title | Comment on ‘Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)’ |
| title_full | Comment on ‘Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)’ |
| title_fullStr | Comment on ‘Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)’ |
| title_full_unstemmed | Comment on ‘Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)’ |
| title_short | Comment on ‘Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)’ |
| title_sort | comment on ‘tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase ii study (td-nice)’ |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389321/ https://www.ncbi.nlm.nih.gov/pubmed/36917134 http://dx.doi.org/10.1097/JS9.0000000000000292 |
| work_keys_str_mv | AT caomeili commentontislelizumabcombinedwithchemotherapyasneoadjuvanttherapyforsurgicallyresectableesophagealcanceraprospectivesinglearmphaseiistudytdnice |